Sodium valproate: pharmacokinetics and effectivensss in treating intractable seizures.
Publication/Presentation Date
1-1-1980
Abstract
Sodium valproate (VPA) was first marketed in the United States in 1978. In this pilot study of pharmacokinetics and toxicity, VPA was added to the treatment regimens of 20 patients (10 adults and 10 children) with intractable seizures. The drug was absorbed and excreted rapidly; the mean half-life was 9.6 hours. Drowsiness and gastrointestinal symptoms were the most common side effects, but they were usually minor and transient. An increase in some plasma phenobarbital levels and a decrease in some plasma phenytoin levels were attributed to drug interaction. Control of absence attacks was assessed by 12-hour telemetered electroencephalograms. Sodium valproate was most efficacious in generalized seizure disorders, particularly absence seizures.
Volume
30
Issue
1
First Page
1
Last Page
6
ISSN
0028-3878
Published In/Presented At
Redenbaugh, J. E., Sato, S., Penry, J. K., Dreifuss, F. E., & Kupferberg, H. J. (1980). Sodium valproate: pharmacokinetics and effectivensss in treating intractable seizures. Neurology, 30(1), 1–6. https://doi.org/10.1212/wnl.30.1.1
Disciplines
Medicine and Health Sciences
PubMedID
6985719
Department(s)
Department of Medicine
Document Type
Article